HRTX
HERON THERAPEUTICS, INC. /DE/
$0.8571
+0.84%
$160.0M
No data for this timeframe.
Vol
Market Cap$160.0M
Cap SizeMicro Cap
Inst. Holders8 funds
Inst. Value$20.2M
Inst. Activity3 buys / 3 sells
SEC Reports6
Recent Activity
May 18, 2026
short_volume
Short Volume: HRTX — 56.8% short (0.6M / 1.0M)
Short: 578,322 | Exempt: 0 | TRF Vol: 1,018,937 | Short Ratio: 56.8% | Off-exchange volume (dark poo
May 11, 2026
SEC
Heron Therapeutics reported Q1 2026 net revenue of $34.7M, down 10.8% YoY, and a GAAP net loss of $8.1M ($-0.04/share) v
PRESS-RELEASE — Impact 6/10
May 11, 2026
SEC
Heron Therapeutics reported Q1 2026 total net revenue of $34.7M, a 10.8% YoY decline from $38.9M, driven by a 26.3% drop
8-K — Impact 6/10
May 6, 2026
Insider
Hensley Mark Earl sold 125,000 shares
Chief Operating Officer @ $0.00 ($0.00)
May 6, 2026
Insider
Hensley Mark Earl sold 125,000 shares
Chief Operating Officer @ $0.00 ($0.00)
Apr 30, 2026
SEC
Heron Therapeutics filed definitive additional proxy materials for its 2026 Annual Meeting scheduled for June 11, 2026.
DEFA14A — Impact 2/10
Apr 30, 2026
Insider
Collard Craig A sold 34,789 shares
Chief Executive Officer @ $0.00 ($0.00)
Inst.
RENAISSANCE TECHNOLOGIES LLC — TRIM
1,915,900 shares ($2.5M)
Price Targets
Historical data — last covering-analyst action Jan 2026. No current recommendation available.
$3.67 (Jan 2026)
Current $0.8571
Low $3.00
Median $4.00
High $4.00
3 analysts
$3.00
$4.00
Analyst Ratings
2Strong Buy
6Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jan 9, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.02 ▼ -100.0% | $-0.02 — $-0.02 | 0% YoY | 1 |
| Next Q | $-0.02 | $-0.02 — $-0.02 | 45% YoY | 1 |
| Current FY | $-0.09 ▼ -200.0% | $-0.09 — $-0.09 | -69% YoY | 1 |
Latest Reports
BEARISH
PRESS-RELEASE
6/10
Heron Therapeutics reported Q1 2026 net revenue of $34.7M, down 10.8% YoY, and a GAAP net loss of $8.1M ($-0.04/share) v
May 11, 2026
BEARISH
8-K
6/10
Heron Therapeutics reported Q1 2026 total net revenue of $34.7M, a 10.8% YoY decline from $38.9M, driven by a 26.3% drop
May 11, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $12.8M | — |
| RENAISSANCE TECHNOLOGIES LLC | $2.5M | TRIM |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $1.8M | NEW |
| TWO SIGMA INVESTMENTS, LP | $1.3M | ADD |
| MORGAN STANLEY | $1.3M | TRIM |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 6, 2026 | Hensley Mark | M | $0.00 |
| May 6, 2026 | Hensley Mark | M | $0.00 |
| Apr 30, 2026 | Collard Craig | M | $0.00 |
| Apr 30, 2026 | Collard Craig | M | $0.00 |
| Apr 30, 2026 | Duarte Ira | M | $0.00 |
8 institutional holders with $20.2M total value (15,513,242 shares) as of 2025-Q4. Top holders: VANGUARD, RENAISSANCE, CHARLES.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 9,820,384 | $12.8M | 63.3% | — |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 1,915,900 | $2.5M | 12.4% | TRIM -32.9% |
| 3 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,415,336 | $1.8M | 9.1% | NEW |
| 4 | TWO SIGMA INVESTMENTS, LP | 999,509 | $1.3M | 6.4% | ADD +44.4% |
| 5 | MORGAN STANLEY | 963,851 | $1.3M | 6.2% | TRIM -60.9% |
| 6 | WELLS FARGO & COMPANY/MN | 179,620 | $233.5K | 1.2% | ADD +45.9% |
| 7 | BANK OF AMERICA CORP /DE/ | 134,445 | $174.8K | 0.9% | NEAR_EXIT -81.6% |
| 8 | FMR LLC | 84,197 | $109.5K | 0.5% | ADD +77.7% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 2,854,999 | 1,915,900 | -32.9% | $2.5M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | ADD | 692,279 | 999,509 | +44.4% | $1.3M | 2025-Q4 |
| MORGAN STANLEY | TRIM | 2,468,041 | 963,851 | -60.9% | $1.3M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 123,132 | 179,620 | +45.9% | $233.5K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 732,073 | 134,445 | -81.6% | $174.8K | 2025-Q4 |
| FMR LLC | ADD | 47,394 | 84,197 | +77.7% | $109.5K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | TRIM | 1,075,269 | 732,073 | -31.9% | $922.4K | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 940,582 | 692,279 | -26.4% | $872.3K | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | TRIM | 258,248 | 123,132 | -52.3% | $155.1K | 2025-Q3 |
| UBS Group AG | DOUBLED | 158,739 | 3,184,965 | +1906.4% | $6.6M | 2025-Q2 |
| MORGAN STANLEY | ADD | 1,933,405 | 2,761,591 | +42.8% | $5.7M | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 77,166 | 258,248 | +234.7% | $534.6K | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 1,188,800 | 2,274,500 | +91.3% | $5.0M | 2025-Q1 |
| MORGAN STANLEY | TRIM | 2,794,190 | 1,933,405 | -30.8% | $4.3M | 2025-Q1 |
| CITADEL ADVISORS LLC | DOUBLED | 61,500 | 551,290 | +796.4% | $1.2M | 2025-Q1 |
| FMR LLC | TRIM | 191,886 | 50,771 | -73.5% | $111.7K | 2025-Q1 |
| MORGAN STANLEY | ADD | 1,768,353 | 2,794,190 | +58.0% | $4.3M | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 2,008,198 | 1,188,800 | -40.8% | $1.8M | 2024-Q4 |
| UBS Group AG | ADD | 85,253 | 159,476 | +87.1% | $244.0K | 2024-Q4 |
| CITADEL ADVISORS LLC | NEAR_EXIT | 1,675,147 | 61,500 | -96.3% | $94.1K | 2024-Q4 |
| MORGAN STANLEY | DOUBLED | 767,861 | 1,768,353 | +130.3% | $3.5M | 2024-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 1,096,385 | — | $2.2M | 2024-Q3 |
10 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 6, 2026 | Hensley Mark Earl | Chief Operating Officer | M | 125,000 | $0.00 | $0.00 |
| May 6, 2026 | Hensley Mark Earl | Chief Operating Officer | M | 125,000 | $0.00 | $0.00 |
| Apr 30, 2026 | Collard Craig A | Chief Executive Officer | M | 34,789 | $0.00 | $0.00 |
| Apr 30, 2026 | Collard Craig A | Chief Executive Officer | M | 34,789 | $0.00 | $0.00 |
| Apr 30, 2026 | Duarte Ira | EVP, Chief Financial Officer | M | 11,694 | $0.00 | $0.00 |
| Apr 30, 2026 | Duarte Ira | EVP, Chief Financial Officer | M | 11,694 | $0.00 | $0.00 |
| Apr 30, 2026 | Forbes William P | EVP, Chief Development Officer | M | 11,694 | $0.00 | $0.00 |
| Apr 30, 2026 | Forbes William P | EVP, Chief Development Officer | M | 11,694 | $0.00 | $0.00 |
| Apr 30, 2026 | Hensley Mark Earl | Chief Operating Officer | M | 11,770 | $0.00 | $0.00 |
| Apr 30, 2026 | Hensley Mark Earl | Chief Operating Officer | M | 11,770 | $0.00 | $0.00 |
| Apr 19, 2026 | Collard Craig A | Chief Executive Officer | M | 13,797 | $0.00 | $0.00 |
| Apr 19, 2026 | Collard Craig A | Chief Executive Officer | M | 13,797 | $0.00 | $0.00 |
| Apr 19, 2026 | Duarte Ira | EVP, Chief Financial Officer | M | 3,874 | $0.00 | $0.00 |
| Apr 19, 2026 | Duarte Ira | EVP, Chief Financial Officer | M | 3,874 | $0.00 | $0.00 |
| Apr 19, 2026 | Forbes William P | EVP, Chief Development Officer | M | 3,874 | $0.00 | $0.00 |
| Apr 19, 2026 | Forbes William P | EVP, Chief Development Officer | M | 3,874 | $0.00 | $0.00 |
| Apr 3, 2026 | Collard Craig A | Chief Executive Officer | M | 62,500 | $0.00 | $0.00 |
| Apr 3, 2026 | Collard Craig A | Chief Executive Officer | M | 62,500 | $0.00 | $0.00 |
| Jan 31, 2026 | Duarte Ira | EVP, Chief Financial Officer | M | 11,695 | $0.00 | $0.00 |
| Jan 31, 2026 | Duarte Ira | EVP, Chief Financial Officer | M | 11,695 | $0.00 | $0.00 |
| Jan 31, 2026 | Forbes William P | EVP, Chief Development Officer | M | 11,695 | $0.00 | $0.00 |
| Jan 31, 2026 | Forbes William P | EVP, Chief Development Officer | M | 11,695 | $0.00 | $0.00 |
| Jan 31, 2026 | Collard Craig A | Chief Executive Officer | M | 34,789 | $0.00 | $0.00 |
| Jan 31, 2026 | Collard Craig A | Chief Executive Officer | M | 34,789 | $0.00 | $0.00 |
| Jan 30, 2026 | Collard Craig A | Chief Executive Officer | A | 800,337 | $0.00 | $0.00 |
| Jan 30, 2026 | Collard Craig A | Chief Executive Officer | A | 800,336 | $0.00 | $0.00 |
| Jan 30, 2026 | Christian Waage | Director | A | 53,960 | $0.00 | $0.00 |
| Jan 30, 2026 | Kaseta Michael | Director | A | 53,960 | $0.00 | $0.00 |
| Jan 30, 2026 | Duarte Ira | EVP, Chief Financial Officer | A | 216,562 | $0.00 | $0.00 |
| Jan 30, 2026 | Duarte Ira | EVP, Chief Financial Officer | A | 216,561 | $0.00 | $0.00 |
| Jan 30, 2026 | Johnson Craig A | Director | A | 53,960 | $0.00 | $0.00 |
| Jan 30, 2026 | Cusack Thomas | Director | A | 53,960 | $0.00 | $0.00 |
| Jan 30, 2026 | Forbes William P | EVP, Chief Development Officer | A | 188,315 | $0.00 | $0.00 |
| Jan 30, 2026 | Forbes William P | EVP, Chief Development Officer | A | 188,314 | $0.00 | $0.00 |
| Jan 30, 2026 | Dissanaike Sharmila | Director | A | 53,960 | $0.00 | $0.00 |
| Jan 30, 2026 | Hensley Mark Earl | Chief Operating Officer | A | 188,315 | $0.00 | $0.00 |
| Jan 30, 2026 | Hensley Mark Earl | Chief Operating Officer | A | 188,314 | $0.00 | $0.00 |
| Jan 30, 2026 | Morgan Adam | Director | A | 53,960 | $0.00 | $0.00 |
6 SEC filing reports analyzed. Sentiment: 0 bullish, 2 bearish, 1 mixed, 3 neutral. Avg impact: 4.2/10.
BEARISH
PRESS-RELEASE
6/10
Heron Therapeutics reported Q1 2026 net revenue of $34.7M, down 10.8% YoY, and a GAAP net loss of $8
May 11, 2026
BEARISH
8-K
6/10
Heron Therapeutics reported Q1 2026 total net revenue of $34.7M, a 10.8% YoY decline from $38.9M, dr
May 11, 2026
NEUTRAL
DEFA14A
2/10
Heron Therapeutics filed definitive additional proxy materials for its 2026 Annual Meeting scheduled
Apr 30, 2026
NEUTRAL
PRESS-RELEASE
1/10
Heron Therapeutics announced it will report Q1 2026 financial results on May 11, 2026. No financial
Apr 27, 2026
NEUTRAL
8-K
4/10
Heron Therapeutics amended and restated employment agreements with CEO Craig Collard and three other
Apr 6, 2026
MIXED
8-K
6/10
Heron Therapeutics reported full-year 2025 net revenue of $154.9 million, up 7.4% year-over-year, dr
Feb 26, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Jan 2026): 89% buy across 9 analysts — 2 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Jan 2026. No current recommendation available.
$3.67 mean target (Jan 2026)
$3.00 Low
$4.00 High
| Metric | Value |
|---|---|
| Current Price | $0.8571 |
| Target Low | $3.00 |
| Target Mean | $3.67 |
| Target Median | $4.00 |
| Target High | $4.00 |
| # Analysts | 3 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.02 | $-0.02 | $-0.02 | 0.0% | -100.0% | — | $0.0B | 13.3% | 1 |
| Next Q 2026-09-30 |
$-0.02 | $-0.02 | $-0.02 | 44.6% | — | — | $0.0B | 18.2% | 1 |
| Current FY 2026-12-31 |
$-0.09 | $-0.09 | $-0.09 | -69.5% | -200.0% | 1↑ 0↓ | $0.2B | 11.8% | 1 |
| Next FY 2027-12-31 |
$0.00 | $0.00 | $0.00 | 100.0% | — | 1↑ 0↓ | $0.2B | 13.5% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.020 | |
| 7d ago | $-0.010 | -0.010 |
| 30d ago | $-0.010 | -0.010 |
| 60d ago | $-0.010 | -0.010 |
| 90d ago | $0.000 | -0.020 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jan 9, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Apr 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Mar 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Feb 1, 2026 | 3 | 6 | 1 | 0 | 0 | 90% | |
| Jan 1, 2026 | 3 | 6 | 1 | 0 | 0 | 90% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 18, 2026
short_volume
Short Volume: HRTX — 56.8% short (0.6M / 1.0M)
Short: 578,322 | Exempt: 0 | TRF Vol: 1,018,937 | Short Ratio: 56.8% | Off-exchange volume (dark pool + OTC)
May 15, 2026
short_volume
Short Volume: HRTX — 63.4% short (0.8M / 1.2M)
Short: 760,990 | Exempt: 633 | TRF Vol: 1,200,798 | Short Ratio: 63.4% | Off-exchange volume (dark pool + OTC)
May 14, 2026
short_volume
Short Volume: HRTX — 55.1% short (0.6M / 1.2M)
Short: 646,727 | Exempt: 0 | TRF Vol: 1,172,933 | Short Ratio: 55.1% | Off-exchange volume (dark pool + OTC)
May 12, 2026
Clinical Trial
A Study of the Boron Neutron Capture Therapy (BNCT) Using B10 L-BPA in Recurrent Meningioma
Phase Phase 2 — COMPLETED
May 11, 2026
earnings
Heron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms Guidance
<p align="justify">CARY, N.C., May 11, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-st
May 11, 2026
earnings_calendar
HRTX Q1 2026 Earnings Scheduled — 2026-05-11
May 11, 2026
short_volume
Short Volume: HRTX — 58.6% short (2.9M / 4.9M)
Short: 2,869,418 | Exempt: 329,031 | TRF Vol: 4,895,612 | Short Ratio: 58.6% | Off-exchange volume (dark pool + OTC)
May 8, 2026
short_volume
Short Volume: HRTX — 59.6% short (0.5M / 0.8M)
Short: 491,237 | Exempt: 12,700 | TRF Vol: 823,633 | Short Ratio: 59.6% | Off-exchange volume (dark pool + OTC)
May 7, 2026
short_volume
Short Volume: HRTX — 67.0% short (0.4M / 0.7M)
Short: 444,876 | Exempt: 281 | TRF Vol: 664,472 | Short Ratio: 67.0% | Off-exchange volume (dark pool + OTC)
May 4, 2026
earnings_calendar
HRTX Q1 2026 Earnings Scheduled — 2026-05-04
May 4, 2026
short_volume
Short Volume: HRTX — 65.0% short (0.7M / 1.1M)
Short: 715,965 | Exempt: 34 | TRF Vol: 1,101,743 | Short Ratio: 65.0% | Off-exchange volume (dark pool + OTC)
May 1, 2026
short_volume
Short Volume: HRTX — 55.1% short (0.8M / 1.5M)
Short: 804,843 | Exempt: 4,789 | TRF Vol: 1,461,903 | Short Ratio: 55.1% | Off-exchange volume (dark pool + OTC)
Apr 29, 2026
short_volume
Short Volume: HRTX — 56.0% short (0.3M / 0.6M)
Short: 335,915 | Exempt: 600 | TRF Vol: 599,828 | Short Ratio: 56.0% | Off-exchange volume (dark pool + OTC)
Apr 27, 2026
earnings
Heron Therapeutics to Report First Quarter 2026 Financial Results on Monday, May 11, 2026
<p align="justify">CARY, N.C., April 27, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-s
Apr 23, 2026
short_volume
Short Volume: HRTX — 68.7% short (0.9M / 1.3M)
Short: 895,282 | Exempt: 3,000 | TRF Vol: 1,304,046 | Short Ratio: 68.7% | Off-exchange volume (dark pool + OTC)
Apr 20, 2026
short_volume
Short Volume: HRTX — 66.8% short (0.5M / 0.7M)
Short: 477,411 | Exempt: 172 | TRF Vol: 714,819 | Short Ratio: 66.8% | Off-exchange volume (dark pool + OTC)
Apr 1, 2026
Clinical Trial
Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1)
Phase Phase 2 — TERMINATED